This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Inovio Pharmaceuticals, Inc.
Drug Names(s): VGX-3100
Description: VGX-3100 is a therapeutic DNA vaccine designed to express the E6 and E7 genes common to HPV types 16 and 18, delivered via in vivo electroporation. VGX-3100 is for patients who already have the papillomavirus infection. The goal is to stimulate the body's immune system to mount a T-cell response strong enough to cause the rejection of these unwanted cells from the body.
Additional information available to subscribers only: